Research Article
Clinical Relevance of NGAL/MMP-9 Pathway in Patients with Endometrial Cancer
Table 4
Comparative analysis according to the prognostic factors for NGAL.
| | Mean | Median | Min | Max | |
| Endometroid/non-endometroid | 176/193 | 175/191 | 132/139 | 190/240 | 0.054 | G1/G2 | 142/161 | 144/168 | 120/126 | 172/180 | 0.081 | G1/G3 | 142/191 | 144/201 | 121/168 | 172/240 | 0.003 | FIGO I and II/FIGO III and IV | 140/220 | 142/226 | 123/178 | 179/280 | 0.001 | Vascular invasion (±) | 152/203 | 149/201 | 120/170 | 179/258 | 0.002 | Lymph vessel invasion (±) | 156/213 | 160/221 | 136/177 | 180/262 | 0.003 | Lymph node metastasis (±) | 155/231 | 157/230 | 131/180 | 179/281 | 0.001 | Infiltrate the myometrium superficial/deep | 158/185 | 156/186 | 140/149 | 182/232 | 0.066 |
|
|